2. Apoptosis Metabolic Enzyme/Protease
  3. Apoptosis Caspase Bcl-2 Family Tyrosinase
  4. Puerarin 6''-O-Xyloside

Puerarin 6''-O-Xyloside  (Synonyms: プエラリン 6''-O-キシロシド)

製品番号: HY-N2135 純度: 99.81%
COA 取扱説明書 Technical Support

Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC50 of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Puerarin 6''-O-Xyloside

Puerarin 6''-O-Xyloside 構造式

CAS 番号 : 114240-18-5

容量 価格（税別） 在庫状況 数量
5 mg $240 在庫あり
10 mg   お問い合わせ  
50 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Other Forms of Puerarin 6''-O-Xyloside:

Puerarin 6''-O-Xyloside 関連抗体

Top Publications Citing Use of Products

Caspase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC50 of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar[1][2][3].

IC50 & Target[1]

Caspase-3

 

Caspase-7

 

Caspase-9

 

Bax

 

Bcl-2

 

体外実験

Puerarin 6''-O-Xyloside (10-40 μM; 32 h) potently inhibits the proliferation of human lung carcinoma A549 cells in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) induces apoptosis in human lung carcinoma A549 cells in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) promotes the release of cytochrome c from mitochondria to the cytoplasm in human lung carcinoma A549 cells in vitro in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) modulates apoptosis-related protein expression in human lung carcinoma A549 cells, significantly upregulating cleaved caspase-3, cleaved caspase-7, cleaved caspase-9, and Bax, while downregulating Bcl-2 in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (5-20 μM; 24-72 h) significantly enhances the proliferation of primary osteoblasts isolated from calvarias of 3-day-old newborn SD rats in a dose-dependent manner[2].
Puerarin 6''-O-Xyloside (5-20 μM; 48 h) significantly decreases RANKL expression, increases OPG expression, and up-regulates the OPG/RANKL ratio in primary osteoblasts isolated from calvarias of 3-day-old newborn SD rats[2].
Puerarin 6''-O-Xyloside (100-1600 μM; 20 min) exhibits dose-dependent inhibitory activity against mushroom tyrosinase with an IC50 of 513.8 μM[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Puerarin 6''-O-Xyloside 関連抗体

Cell Viability Assay[1]

Cell Line: human lung carcinoma A549 cells
Concentration: 10 μM; 20 μM; 40 μM
Incubation Time: 32 h
Result: Reduced cell viability in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line: human lung carcinoma A549 cells
Concentration: 10 μM; 20 μM; 40 μM
Incubation Time: 32 h
Result: Induced apoptosis in A549 cells in a concentration-dependent manner.
Increased the percentage of total apoptotic cells (early + late) progressively with rising concentrations.
Observed the highest apoptosis rate at 40 μM.

Western Blot Analysis[1]

Cell Line: human lung carcinoma A549 cells
Concentration: 10 μM; 20 μM; 40 μM
Incubation Time: 32 h
Result: Increased cytoplasmic cytochrome c levels in a concentration-dependent manner.
Decreased mitochondrial cytochrome c levels in a concentration-dependent manner.
Upregulated cleaved caspase-3, caspase-7, caspase-9 protein levels in a concentration-dependent manner.
Upregulated Bax protein levels in a concentration-dependent manner and downregulated Bcl-2 protein levels in a concentration-dependent manner.
体内実験

Puerarin 6''-O-Xyloside (40 mg/kg; i.p.) significantly suppresses A549 tumour growth in nude mice without causing significant body weight changes[1].
Puerarin 6''-O-Xyloside (20-60 mg/kg; i.p.; after 12 weeks of OVX operation) exerts significant dose-dependent anti-osteoporotic activity in ovariectomized mice, as evidenced by reduced body weight, increased uterine index, elevated serum Ca2+, phosphorus, ALP, and OPG levels, and improved bone histology[2].
Puerarin 6''-O-Xyloside (10-80 mg/kg; i.p.; single dose) shows no acute toxicity in healthy female ICR mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice were injected in the right flank subcutane-
ously with A549 cells[1]
Dosage: 40 mg/kg
Administration: i.p.
Result: Significantly suppressed A549 tumour growth during a 15 d observation period.
Showed no significant difference in body weight relative to control mice.
Animal Model: ICR (female, 3-month-old, bilateral ovariectomy-induced)[2]
Dosage: 20 mg/kg; 40 mg/kg; 60 mg/kg
Administration: i.p.; daily; 12 weeks
Result: Decreased body weights of ovariectomized mice relative to untreated controls at 40 and 60 mg/kg.
Increased uterine index in a dose-dependent manner compared to untreated controls.
Increased serum blood calcium, phosphorus, alkaline phosphatase (ALP), osteoprotegerin (OPG) levels in a dose-dependent manner relative to untreated controls.
Improved osteoporotic bone changes (thickened compact bone, thicker/more compact trabecular bone) at all tested doses; yielded nearly normal femur tissue morphology at 60 mg/kg.
分子量

548.49

分子式

C26H28O13
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

OC1=CC=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=C1[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO[C@H](OC[C@@H](O)[C@@H]5O)[C@@H]5O
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (182.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8232 mL 9.1159 mL 18.2319 mL
5 mM 0.3646 mL 1.8232 mL 3.6464 mL
10 mM 0.1823 mL 0.9116 mL 1.8232 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 99.81%

COA (253 KB) HNMR (278 KB) LCMS (102 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8232 mL 9.1159 mL 18.2319 mL 45.5797 mL
5 mM 0.3646 mL 1.8232 mL 3.6464 mL 9.1159 mL
10 mM 0.1823 mL 0.9116 mL 1.8232 mL 4.5580 mL
15 mM 0.1215 mL 0.6077 mL 1.2155 mL 3.0386 mL
20 mM 0.0912 mL 0.4558 mL 0.9116 mL 2.2790 mL
25 mM 0.0729 mL 0.3646 mL 0.7293 mL 1.8232 mL
30 mM 0.0608 mL 0.3039 mL 0.6077 mL 1.5193 mL
40 mM 0.0456 mL 0.2279 mL 0.4558 mL 1.1395 mL
50 mM 0.0365 mL 0.1823 mL 0.3646 mL 0.9116 mL
60 mM 0.0304 mL 0.1519 mL 0.3039 mL 0.7597 mL
80 mM 0.0228 mL 0.1139 mL 0.2279 mL 0.5697 mL
100 mM 0.0182 mL 0.0912 mL 0.1823 mL 0.4558 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Puerarin 6''-O-Xyloside Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Puerarin 6''-O-Xyloside114240-18-5ApoptosisCaspaseBcl-2 FamilyTyrosinasehuman lung carcinoma A549 cellsmelanomanude micehuman lung carcinomaapoptosisAgaricus bisporus mushroom tyrosinaseosteoporosisprimary osteoblaststyrosinaseskin tumorInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Puerarin 6''-O-Xyloside
製品番号:
HY-N2135
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.